Boston Scientific Corporation
bostonscientific.comTotal trials
530
Active
71
Phase 3
57
Total enrollment
246,038
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Anticoagulation with heparin | — | — | — | — | — | 1 | |
| TheraSphere™ Yttrium-90 Glass Microspheres | — | — | — | — | — | 1 | |
| Durvalumab (Imfinzi) immunotherapy | — | — | — | — | — | 1 | |
| Tremelimumab immunotherapy | — | — | — | — | — | 1 | |
| Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone | — | — | — | — | — | 1 | |
| alpha blocker and 5-alpha reductase inhibitor | — | — | — | — | — | 1 | |
| Non-Vitamin K Oral Anticoagulant | — | — | — | — | — | 1 |
Next readouts
- 2025-07-31
- 2025-12-11
- 2026-02-04
- 2026-02-13
- 2027-06
- 2027-12
Top conditions
- Coronary Artery Disease44
- Heart Failure40
- Atrial Fibrillation27
- Chronic Pain27
- Paroxysmal Atrial Fibrillation20
- Atherosclerosis15
- Pain14
- Bradycardia13
Frequently asked questions about Boston Scientific Corporation
- How many clinical trials does Boston Scientific Corporation have on ClinicalTrials.gov?
- Boston Scientific Corporation is listed as the lead sponsor on 530 clinical trials in ClinicalTrials.gov, 71 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Boston Scientific Corporation's trials are in Phase 3?
- 57 of Boston Scientific Corporation's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does Boston Scientific Corporation focus on?
- Boston Scientific Corporation's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Heart Failure, Atrial Fibrillation, Chronic Pain, Paroxysmal Atrial Fibrillation.
- When are Boston Scientific Corporation's next clinical trial readouts?
- Boston Scientific Corporation has 6 upcoming primary-completion readouts tracked here; the soonest is “Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism”, expected around 2025-07-31.